USPTO Examiner DAHLE CHUN WU - Art Unit 1641

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18598342ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOFMarch 2024August 2024Allow610NoNo
18440895Fc VARIANTS WITH ALTERED BINDING TO FcRnFebruary 2024June 2024Abandon400NoNo
18420507SINGLE DOMAIN ANTIBODIES TO INFLUENZA HEMAGGLUTININ A AND BJanuary 2024April 2024Allow301YesNo
18542031PEPTIDES AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICADecember 2023December 2024Abandon1201NoNo
18501413ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023January 2024Allow300NoNo
18501419ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023June 2024Allow820YesNo
18501427ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORNovember 2023July 2024Allow920YesNo
18358738GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINESJuly 2023May 2025Abandon2231NoNo
18253999METHOD FOR MAXIMIZING CORONAVIRUS KILLING ACTIVITY OF HIGH-DENSITY LIPOPROTEINS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COVID-19May 2023February 2025Allow2131NoNo
18050216GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINESOctober 2022September 2024Abandon2211NoNo
17934785ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM 2DD8September 2022June 2025Allow3300NoNo
17861920AGLYCOSYLATED ANTIBODY Fc REGION FOR TREATING CANCERJuly 2022February 2025Allow3200YesNo
17855543FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOFJune 2022August 2023Allow1311YesNo
17804934Anti-FcRn AntibodiesJune 2022February 2025Allow3300YesNo
17725417ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USEApril 2022May 2025Allow3701YesNo
17696364THERAPEUTIC NUCLEASE COMPOSITIONS AND METHODSMarch 2022May 2025Allow3811NoNo
17666107NOVEL ANTIGEN BINDING MOLECULE FORMATSFebruary 2022July 2024Allow2931YesYes
17588094ANTI-DLL4/VEGF DUAL VARIABLE DOMAIN IMMMUNOGLOBULIN AND USES THEREOFJanuary 2022May 2024Allow2800YesNo
17578655HUMANIZED ANTI-HUMAN CD19 ANTIBODIES AND METHODS OF USEJanuary 2022September 2024Allow3210NoNo
17569107BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 AND CD20January 2022May 2025Abandon4101NoNo
17645619METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFDecember 2021December 2024Allow3621YesNo
17549706Fc VARIANTS WITH ALTERED BINDING TO FcRnDecember 2021September 2024Allow3310NoNo
17643506ANTIBODIES SPECIFIC TO FCRNDecember 2021September 2024Abandon3410YesNo
17534712ANTIBODIES AND METHODS OF USE THEREOF IN TREATMENT OF INFECTIOUS DISEASENovember 2021April 2025Abandon4001NoNo
17535507Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating MethodsNovember 2021September 2024Abandon3410NoNo
17527741ENGINEERED Fc CONSTRUCTSNovember 2021July 2023Allow2001YesNo
17514824HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USEOctober 2021February 2024Allow2800YesNo
17491677COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTSOctober 2021January 2025Allow4001YesNo
17408113ANTIBODY SPECIFIC FOR CD22 AND METHODS OF USE THEREOFAugust 2021June 2024Allow3410YesNo
17400367FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONSAugust 2021May 2024Allow3300NoNo
17304412I DOMAIN CHIMERIC ANTIGEN RECEPTOR SPECIFIC TO ICAM-1June 2021May 2025Allow4711YesNo
17346648ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFEJune 2021December 2023Allow3000YesNo
17324641Therapeutic Nuclease Compositions and MethodsMay 2021January 2025Allow4410NoNo
17288245ENGINEERED FCApril 2021November 2024Abandon4201NoNo
17235854USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTSApril 2021June 2024Abandon3801NoNo
17234695HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USEApril 2021November 2023Allow3100NoNo
17228817DE NOVO BINDING DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOFApril 2021March 2025Allow4711NoNo
17266377METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CNS OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE, AND PALMITOYL-PROTEIN THIOESTERASE 1February 2021June 2025Abandon5311NoNo
17259498COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTSJanuary 2021November 2024Abandon4601NoNo
17259480COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTSJanuary 2021September 2024Abandon4401NoNo
17145052AGONISTIC ANTIBODIES THAT BIND CD40January 2021August 2024Abandon4321NoYes
17129031Fc VARIANTS THAT IMPROVE FcRn BINDING AND/OR INCREASE ANTIBODY HALF-LIFEDecember 2020February 2024Abandon3810NoNo
17251316ANTIBODY-OLIGONUCLEOTIDE CONJUGATESDecember 2020January 2025Allow4921YesNo
16972840ANTI-SIGLEC-7 ANTIBODIES AND METHODS OF USE THEREOFDecember 2020October 2024Allow4611YesNo
17107217STABLE HETERODIMERIC ANTIBODY DESIGN WITH MUTATIONS IN THE Fc DOMAINNovember 2020January 2025Abandon4911NoNo
17056385FC-EPSILON CARNovember 2020June 2025Allow5541YesNo
17079299Fc VARIANTS WITH ALTERED BINDING TO FcRnOctober 2020September 2023Allow3501YesNo
17049093HIGHLY SIALYLATED AUTOANTIBODIES AND USES THEREOFOctober 2020May 2024Abandon4311NoNo
17035015HETERODIMERIC PROTEINSSeptember 2020September 2024Abandon4721NoNo
17029185METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLSSeptember 2020January 2024Abandon4010NoNo
16981367NOVEL ANTI-TIM-3 ANTIBODIESSeptember 2020September 2024Allow4821YesNo
16997808ANTIBODY FC VARIANTSAugust 2020November 2023Abandon3901NoNo
16990421COMPOSITIONS AND METHODS FOR TREATING ANTIBODY RESISTANCEAugust 2020December 2023Abandon4001NoNo
16967216ANTIBODY VARIABLE DOMAINS TARGETING THE NKG2D RECEPTORAugust 2020August 2023Allow3701YesNo
16985119Fc VARIANTS WITH ALTERED BINDING TO FcRnAugust 2020October 2024Abandon5021NoNo
16942615OPTIMIZED Fc VARIANTSJuly 2020August 2023Allow3711NoNo
16947021STABLE IgG4 ANTIBODIESJuly 2020June 2024Abandon4711NoNo
16921506TRANSFERRIN RECEPTOR-BINDING POLYPEPTIDES AND USES THEREOFJuly 2020September 2024Abandon5021NoNo
16921154ANTIBODY VARIANTS AND USES THEREOFJuly 2020March 2024Allow4411NoNo
16771377Bispecific CD16-Binding Molecules and Their Use in the Treatment of DiseaseJune 2020June 2023Allow3610YesNo
16883273HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASEMay 2020October 2023Allow4111YesNo
16839777COMBINATIONS AND USES THEREOFApril 2020January 2024Abandon4621NoNo
16839903COMBINATIONS AND USES THEREOFApril 2020February 2024Abandon4721NoNo
16830063Fc VARIANTS WITH ALTERED BINDING TO FcRnMarch 2020March 2024Abandon4741NoNo
16649893PROTEINACEOUS HETERODIMER AND USE THEREOFMarch 2020February 2024Allow4651YesNo
16645613PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1)March 2020May 2025Abandon6051NoNo
16795676MODIFIED Fc REGION OF ANTIBODYFebruary 2020November 2024Allow5631YesNo
16639150PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGENFebruary 2020May 2024Abandon5141YesYes
16631062NEW TARGET FOR TREATING CANCERJanuary 2020September 2024Abandon5601NoNo
16628722NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOFJanuary 2020November 2024Abandon5971YesNo
16717671Antibodies of the Class IGG4December 2019June 2024Allow5441YesNo
16700937ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR CD19December 2019April 2023Allow4011YesNo
16612867ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONSNovember 2019December 2023Abandon4932YesNo
16679483COMBINATION THERAPY OF AN ANTI CD20 ANTIBODY WITH A BTK INHIBITORNovember 2019September 2024Allow5840YesYes
16590938FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USEOctober 2019December 2024Allow6051YesNo
16590143HYBRID IMMUNOGLOBULINS WITH MOVING PARTSOctober 2019May 2025Allow6031YesNo
16483738COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALINGAugust 2019December 2023Abandon5222NoNo
16437571FcgammaRIIB-Specific Antibodies and Methods of Use ThereofJune 2019November 2023Abandon5341NoNo
16345620FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFEApril 2019April 2025Abandon6061NoNo
16341437COMPOSITIONS AND METHODS FOR NON-MYELOABLATIVE CONDITIONINGApril 2019June 2025Abandon6041YesYes
16315356FC MUTANTS WITH IMPROVED FUNCTIONAL ACTIVITYJanuary 2019July 2023Allow5452YesNo
16213422USE OF FCRN ANTAGONISTS FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVISDecember 2018October 2024Allow6061NoYes
16017967IMMUNOMODULATORY PROTEINSJune 2018August 2024Abandon6061YesYes
15742268USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPYJanuary 2018November 2024Allow6071YesNo
15741590FUSION PROTEINS WHICH BIND TO HUMAN FC RECEPTORSJanuary 2018April 2025Abandon6081YesNo
15860163HETERODIMERIZED POLYPEPTIDEJanuary 2018April 2025Allow6061YesYes
15696138HOMOGENEOUS ANTIBODY POPULATIONSSeptember 2017June 2021Abandon4661YesYes
15667309ENGINEERED POLYPEPTIDES AND USES THEREOFAugust 2017October 2022Allow6041YesNo
15616416HUMANIZED ANTI-CD22 ANTIBODYJune 2017February 2018Allow811YesNo
15263449HUMANIZED ANTI-CD22 ANTIBODYSeptember 2016April 2017Allow711NoNo
15123066MULTIMERIC FC PROTEINSSeptember 2016September 2024Abandon6091NoYes
15036209ANTIBODIES SPECIFIC TO FCRNMay 2016December 2018Allow3111YesNo
14886978ANTIBODY DERIVATIVESOctober 2015September 2018Allow3511YesNo
14824751HUMANIZED ANTI-CD22 ANTIBODYAugust 2015September 2016Allow1312YesNo
14295579Combination of FcgammaRIIB-Specific Antibodies and CD20-Specific Antibodies and Methods of Use ThereofJune 2014April 2017Allow3501YesNo
14211604DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1 AND/OR IL-17March 2014March 2015Allow1201YesNo
14195885ANTI-TNF-ANTI-IL-17 BISPECIFIC ANTIBODIESMarch 2014April 2016Allow2611YesNo
13851625AntibodiesMarch 2013June 2014Allow1500NoNo
13846188IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT FC REGIONS AND METHODS OF USING SAMEMarch 2013September 2014Allow1811YesNo
13772063HUMAN ANTIBODIES THAT BIND CD22 AND USES THEREOFFebruary 2013July 2016Allow4121YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAHLE, CHUN WU.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
1
(33.3%)
Examiner Reversed
2
(66.7%)
Reversal Percentile
85.3%
Higher than average

What This Means

With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
20
Allowed After Appeal Filing
3
(15.0%)
Not Allowed After Appeal Filing
17
(85.0%)
Filing Benefit Percentile
15.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DAHLE, CHUN WU - Prosecution Strategy Guide

Executive Summary

Examiner DAHLE, CHUN WU works in Art Unit 1641 and has examined 151 patent applications in our dataset. With an allowance rate of 72.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner DAHLE, CHUN WU's allowance rate of 72.2% places them in the 27% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by DAHLE, CHUN WU receive 1.99 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DAHLE, CHUN WU is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +41.3% benefit to allowance rate for applications examined by DAHLE, CHUN WU. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.2% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.8% of cases where such amendments are filed. This entry rate is in the 36% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.5% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 13.2% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.7% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.